Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?

C Zoccali

Journal: Kidney international 2007;70(12):2053-5

PMID: 17136131

Free Full Text on Elsevier Science View on PubMed

Abstract

The nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) is an emerging risk biomarker in cardiovascular and renal diseases. Apparently amlodipine and valsartan produce substantial reductions in the plasma concentration of this methylarginine in hemodialysis patients. These findings are of relevance for designing studies aimed at testing the etiologic relevance of ADMA to the high cardiovascular risk of ESRD.

Address: Epidemiologia Clinica e Fisiopatologia delle malattie Renali e dell'Ipertensione Arteriosae Unita Operativa di Nefrologia, Dialisi e Trapianto Renale, Ospedali Riuniti, Reggio Calabria, Italy. [email protected]

DOI: 10.1038/sj.ki.5001898

Link outs

Free resources

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0085...

Medical:

https://medlineplus.gov/kidneyfailure.html

Subscription / membership required

Full Text Sources:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linko...

MeSH Terms: Amlodipine, Angiotensin II, Angiotensin II Type 1 Receptor Blockers, Arginine, Biomarkers, Calcium, Calcium Channel Blockers, Humans, Kidney Failure, Chronic, Risk Factors, Tetrazoles, Valine, Valsartan